Comparative Pharmacology
Head-to-head clinical analysis: FORBAXIN versus PYOCIDIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FORBAXIN versus PYOCIDIN.
FORBAXIN vs PYOCIDIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FORBAXIN is a prodrug of the active moiety cefditoren, a cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Pyocidin is a bactericidal antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
IV: 500 mg every 12 hours, infused over 30 minutes.
5 mg/kg intramuscular or subcutaneous every 24 hours. Max dose 300 mg per injection.
None Documented
None Documented
8-12 hours; prolonged in renal impairment (up to 24 hours in severe cases)
Terminal elimination half-life is 2-3 hours in patients with normal renal function; extends to 12-18 hours in severe renal impairment (CrCl <30 mL/min).
Renal (60-70% unchanged), biliary/fecal (20-30%)
Primarily renal excretion of unchanged drug (60-70%), with 20-30% biliary excretion and minor fecal elimination (<10%).
Category C
Category C
Antibiotic
Antibiotic